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Background: Glioblastoma multiforme (GBM) has a dismal prognosis despite 
aggressive therapy. Initial diagnosis and measurement of response to treatment 
is usually determined by measurement of gadolinium-enhanced tumor volume with 
magnetic resonance imaging (MRI). Unfortunately, many GBM treatment modalities 
can cause changes in tumor gadolinium enhancement patterns that mimic tumor 
progression. The lack of a defi nitive imaging modality to distinguish posttreatment 
radiographic imaging changes (PTRIC), including pseudoprogression and radiation 
necrosis, from true tumor progression presents a major unmet clinical need in the 
management of GBM patients.
Methods: The authors discuss current modalities available for differentiating PTRIC 
and tumor progression, describe development of an animal model of PTRIC, and 
consider potential molecular and cellular pathways involved in the development 
of PTRIC.
Results: An animal model using glioma cells transfected with a luciferase reporter 
has been developed, and after conventional GBM therapy, this animal model can 
be evaluated with posttreatment bioluminescence imaging and various MR tumor 
imaging modalities.
Conclusions: Posttreatment radiographic changes that mimic tumor progression 
can infl uence clinicians to make treatment decisions that are inappropriate for the 
patient’s actual clinical condition. Several imaging modalities have been used to try 
to distinguish PTRIC and true progression, including conventional MRI, perfusion 
MRI, MR spectroscopy, and positron emission tomography (PET); however, none 
of these modalities has consistently and reliably distinguished PTRIC from tumor 
growth. An animal model using glioma cells transfected with a luciferase reporter 
may enable mechanistic studies to determine causes and potential treatments for 
PTRIC.
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INTRODUCTION
Glioblastoma multiforme (GBM), the most common and 
most malignant brain tumor in humans, has a dismal 
prognosis despite aggressive therapy. Initial diagnosis and 
measurement of response to treatment is usually determined 
by measurement of gadolinium-enhanced tumor volume 
with magnetic resonance imaging (MRI). Unfortunately, 
many GBM treatment modalities can cause changes in 
tumor gadolinium enhancement patterns that mimic tumor 
progression. These changes are usually found to improve or 
remain stable on follow-up MRI and have thus been termed 
“pseudoprogression”.[4-7,9-11,14,18,36] The lack of a definitive 
imaging modality to distinguish posttreatment radiographic 
imaging changes (PTRIC), including pseudoprogression and 
radiation necrosis, from true tumor progression presents 
a major unmet clinical need in the management of GBM 
patients.[36] To date, no single imaging modality, including 
MRI, magnetic resonance spectroscopy (MRS), and positron 
emission tomography (PET), has been successful in making 
this determination. At present, only direct examination of 
tumor histopathology can discriminate tumor progression 
from PTRIC. Furthermore, there is no clear understanding 
of the molecular, biochemical, and cellular mechanisms 
mediating PTRIC.
CLINICAL PROBLEM OF 
PSEUDOPROGRESSION AND 
RADIATION NECROSIS
Among patients on temozolomide (TMZ) therapy with early 
progression in the first 3 months, approximately one-third 
were found to have pseudoprogression/PTRIC.[31] What 
makes pseudoprogression so difficult clinically is that an 
incorrect diagnosis of progression could result in termination 
of an effective treatment because of apparent lack of 
response. This could have a negative influence on survival 
if a less effective treatment is instituted. Pseudoprogression 
differs from radiation necrosis in that the increase in contrast 
enhancement is transient and resolves without changes in 
management with the former, whereas clinical worsening 
is more likely with the latter [Figure 1].[32] Follow-up scans 
offer the best indication of pseudoprogression, because true 
tumor and enhancement changes due to other variables 
cannot be differentiated with current imaging techniques.[20]
PTRIC AND TUMOR BIOLOGY
Pseudoprogression usually occurs in patients that have 
received TMZ therapy combined with radiotherapy. 
The rapid onset in patients treated with both radio- and 
chemotherapy suggests the presence of damage to both the 
neuroglia and the vasculature supplying it. The biology of 
pseudoprogression is not entirely clear as several hypotheses 
have been proposed. The alkylating agent TMZ causes 
replication arrest in the G2/M cell cycle phase and increases 
the number of breaks in DNA. Radiation therapy has 
similar mechanistic events. It has been proposed that the 
combination of these effects sets in motion an exaggerated 
cellular response within the tumor cells, in the surrounding 
astrocytes, or in the peritumoral vasculature that 
subsequently results in imaging changes consistent with 
pseudoprogression.[7] Why this does not happen in every 
case of GBM treated with this therapeutic regimen remains 
a question. A recent study showed the level of cellular 
proliferation, as measured by Ki67 index at the time of 
initial surgery, can be a prognostic marker for distinguishing 
pseudoprogression from actual progression.[28] Higher levels 
of Ki67 expression were associated with development of 
pseudoprogression on follow-up imaging studies. True 
progression of GBM, in contrast, was associated with initial 
lower levels of cellular proliferation. Further studies need to 
be done to confirm this finding, which from a mechanistic 
standpoint seems paradoxical. Interestingly, patients with 
a malignant glioma who developed pseudoprogression 
were found to have a more favorable prognosis than 
patients without development of this radiological 
phenomenon.[7] It has been hypothesized that these 
Figure 1: MRIs showing imaging pseudoprogression in a 51-year-old man with a left frontal heterogeneously enhancing mass (Preoperative). 
After surgical resection (Postoperative), histological evaluation was consistent with glioblastoma. The patient was then treated with 
fractionated radiotherapy with concurrent temozolomide (PostXRT). At the end of two cycles of adjuvant temozolomide, a new enhancing 
lesion was found in the mesial posterior resection cavity, which suggested a recurrent tumor (Postcycle 2 adjuvant TMZ). After two more 
cycles of TMZ, the enhancing lesion resolved, suggesting that the enhancement had been due to pseudoprogression (Postcycle 4 adjuvant 
TMZ). There was no further development of enhancement within the resection bed throughout the completion of 12 total adjuvant TMZ 
cycles (Postcycle 12 adjuvant TMZ) and even after 1 year off of any therapy (1 year off treatment)
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patients may be genetically predisposed to respond to TMZ 
with O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation. This marker was reported to be an 
important prognostic factor in GBM as the development 
of pseudoprogression was significantly correlated with the 
MGMT promoter methylation status.[6]
MR IMAGING, MR SPECTROSCOPY, 
AND PTRIC
The standard of care for measurement of response 
to treatment is gadolinium-enhanced MRI; however, 
conventional MRI is not always helpful at distinguishing 
pseudoprogression. When evaluating patient tumor 
response, it is well known that conventional MRI does 
not reliably distinguish radiation necrosis from tumor 
recurrence after stereotactic radiosurgery.[33] In a similar 
fashion, conventional MRI has little use in diagnosing 
pseudoprogression in glioblastoma, although it has been 
demonstrated that subependymal spread of enhancing 
lesion is found more commonly in tumor progression 
rather than in pseudoprogression.[39]
Other forms of MRI that have been evaluated also do 
not consistently or reliably discriminate PTRIC from true 
progression. This is especially true during bevacizumab 
therapy for recurrent GBM. In fact, a nonenhancing 
tumor pattern of progression is common after treatment 
with bevacizumab for GBM but does not necessarily 
translate into improved survival.[21] Diffusion-weighted 
MRI can be helpful in differentiation of true progression 
from pseudoprogression after concomitant radiotherapy 
with TMZ in patients with newly diagnosed high-grade 
gliomas.[26] Patients with pseudoprogression also 
have lower diffusion-weighted imaging (DWI) signal 
intensity (rim of high or no signal intensity pattern) and 
higher apparent diffusion coefficient (ADC) values than 
the patients with true progression.[26,37]
Attempts have been made to use perfusion MRI to 
estimate tumor burden, as opposed to pseudoprogression 
or radiation necrosis, and have correlated this 
with overall patient survival.[19,38] Regional cerebral 
blood volume (rCBV) measured by dynamic 
susceptibility-weighted contrast-enhanced perfusion MR 
images has been used to help predict pseudoprogression 
in patients with GBM,[23] with a significantly lower mean 
rCBV demonstrated in pseudoprogression compared with 
real tumor progression. Despite the promise of these 
findings, in our experience, patients often have a mixed 
pattern of perfusion, suggestive of both tumor progression 
and pseudoprogression, which makes interpretation of this 
imaging modality no matter how elegant or sophisticated, 
very difficult. Our group has recently finished a prospective 
clinical trial measuring MR perfusion from various areas 
within a given tumor and correlated this with hypoxia 
tumor markers. We found very different expression of 
hypoxia-regulated proteins and perfusion MR in different 
areas of a given tumor (unpublished data). This implies 
that regional differences in MR perfusion might hamper 
interpretation of these measurements in de novo tumor 
and would be even more complicated in a treated tumor 
with suspected PTRIC.
MR spectroscopy was initially thought to differentiate 
between radiation necrosis and tumor progression but 
has proved not to be completely effective.[20,30,39] MR 
spectroscopy can, however, depict structural degradation 
in cerebral tissues after radiation therapy and can show 
alterations in brain metabolites. MR spectroscopy has 
not been shown to be very effective in distinguishing 
pseudoprogression and true tumor progression,[20] most 
likely because of sampling issues and mixed tumor/
pseudoprogression content of voxels being interrogated.
PET IMAGING AND PTRIC
Positron emission tomography, with its ability to measure 
metabolic activity, has been proposed as an imaging 
modality with high potential to distinguish between 
pseudoprogression, true progression, and radiation necrosis. 
PET imaging has allowed highly sensitive measurements to 
be taken of biochemically active molecules using labeled, 
short-lived positron-emitting radionuclides. The most 
common PET imaging tracer for clinical use is the glucose 
analog 2-deoxy-2-(18F) fluoro-D-glucose, also called 
18fluorodeoxyglucose ([18F] FDG), whose function in PET 
imaging is based on the principle of glycolytic metabolism; 
areas with high activity correspond to increased glucose 
metabolism commonly found in tumors. In contrast, the 
dead tissue of radiation necrosis or pseudoprogression 
should have low radionucleotide uptake and activity. PET 
imaging is increasingly implemented in neuro-oncology 
since it can provide a metabolic component to measure 
a specific pathway in a given tumor or tumor cell.
[18F] FDG PET is useful for imaging gliomas because 
high-grade gliomas have increased glucose metabolism, 
which can be identified on [18F] FDG PET; however, 
current data on [18F] FDG PET are inconsistent and show 
limited accuracy for the differentiation between tumor 
progression and the imaging changes that are the subject 
of this review.[25] This is probably related to sampling issues 
described earlier as well as the lower spatial resolution of 
this imaging modality.
ANIMAL MODELS OF RADIATION NECROSIS
As described earlier, there is a significant lack of 
understanding of the molecular underpinnings behind the 
development of PTRIC. One significant step toward this 
end would be the development of a model to elucidate 
these pathways. To date, there is no animal model of 
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PTRIC. There have been attempts to develop a radiation 
necrosis rodent model using a 4-mm radiosurgery cone 
to deliver 60 Gy to an implanted GBM cell line.[24] 
Histological evaluation of the brains of rats with implanted 
irradiated GBM cells showed central liquefaction necrosis 
in high-dose regions consistent with necrosis and viable 
tumor growth in low-dose regions. A similar mouse glioma 
model has also shown changes in MR perfusion and 
diffusion after radiation treatments.[12] This same model 
has demonstrated similar MR perfusion and diffusion 
changes after combination chemo- and radiation therapy.[12] 
Diffusion tensor MRI has been reported to be helpful in 
distinguishing radiation necrosis and viable glioma in a rat 
radiation necrosis model.[35] In lesions caused by radiation 
necrosis, a visible isotropic ADC pattern was observed. 
Areas that were hypointense, the central necrotic zone, 
corresponded to a lower ADC, while areas that were 
hyperintense, the peripheral zone, corresponded to a higher 
ADC. Histological analysis showed parenchymal coagulative 
necrosis in the central zone and damaged vessels and 
reactive gliosis in the peripheral zones.
Magnetically labeled cytotoxic T-cells (CTLs) have been 
used to differentiate glioma progression from radiation 
injury in a rat model.[2] Dendritic cells were primed 
with glioblastoma tumor cell lysates to generate CTLs 
sensitized to these tumor cells. These labeled CTLs were 
injected into rats with implanted tumors as well as rats 
with focal radiation injury. MRIs showed accumulation of 
CTLs in actively growing tumor areas and not at sites of 
radiation necrosis. Radiation necrosis is much easier to 
model than PTRIC given the reversible nature of PTRIC 
and the fact that radiation necrosis can be induced 
simply by high-dose radiation treatment.
PRELIMINARY WORK ON AN ANIMAL 
MODEL OF PTRIC
We have begun to develop an animal model of PTRIC 
using established glioma cell lines and hope to extend 
this to tumor-derived GBM stem cells. Nonirradiated, 
sublethally irradiated, and lethally irradiated brain tumor 
cells were transfected with a constitutively active luciferase 
reporter and stereotactically implanted into rats. The rats 
were then treated with TMZ chemotherapy and received 
either no irradiation, sublethal irradiation (2 Gy), or 
lethal irradiation (10 Gy) to the implanted tumor cells 
and surrounding brain. Cell growth was monitored by 
bioluminescence imaging of the luciferase reporter and 
brain MRI measurement of tumor growth [Figures 2 and 3].
We then evaluated which combination of preimplanted 
cellular conditioning (no, sublethal, or lethal irradiation) 
and postimplantation conditions (chemotherapy alone 
or with sublethal or lethal radiation) shows MRI 
enhancement after radiation and chemotherapy while 
demonstrating decreasing luciferase activity. Rats were also 
imaged weekly when intracranial tumor luciferase activity 
was found. We have previously demonstrated that 
luciferase activity is correlated with intracranial tumor 
proliferation.[22,29] We hypothesize that comparing patterns 
of luciferase activity with tumor gadolinium enhancement 
measured by MRI will allow us to differentiate between 
tumor progression, pseudoprogression, and radiation 
necrosis. We predict that tumor progression would be 
manifested by high and weekly increasing luciferase 
activity coupled with increasing gadolinium-enhanced 
tumor volume [Figure 2]. Similarly, we would expect 
pseudoprogression to be modeled by weaker and 
weekly decreasing luciferase activity with increasing 
gadolinium-enhanced tumor volume over time [Figure 3]. 
In the future, we plan to perform histological and 
immunological analysis of the treated brain and tumor, as 
well as measure vascularity, apoptosis, proliferation, and 
various signaling molecules to further work out this model. 
Our plans also include experiments using the hypoxia 
marker pimonidazole and perfusion marker Hoechst 
33342 for measurement of tumor vascular perfusion to 
allow for the determination of tumor blood flow and 
its relationship to areas of hypoxia for correlation with 
imaging data. Tumor histology will be confirmed by light 
microscopy and MIB-1 (for proliferative index), Factor-8 
or CD31 (for vascularity), Caspase-3 (for apoptosis) 
evaluation. Hypoxia-regulated protein expression, 
including hypoxia-inducible factor-1 (HIF-1), 
vascular endothelial growth factor (VEGF), carbonic 
anhydrase-IX (CA-IX), glucose transporter-1 (Glut-1), 
stromal cell-derived factor-1 (SDF-1), and CXC chemokine 
ligand 12 (CXC-12), will be immunohistochemically 
analyzed for preliminary study of the role of these 
proteins in pseudoprogression development. The 
histological measures will be correlated with PET tracer 
studies using 15O H2O for perfusion, 
18F-misonadozole 
for hypoxia, 18F-flurodoxythymidine for proliferation, 
and 18F-deoxyglucose for tumor metabolic activity to 
demonstrate the ability of these tracers (or combination 
of tracers) to differentiate between pseudoprogression, 
radiation necrosis, and tumor progression. We will 
eventually expand these studies to include subjecting 
the cell to be implanted to hypoxic conditions (with or 
without irradiation) before placement into the rat brain. 
We will also study glioma cells with inhibited HIF-1 
pathways or overexpression of these pathways.
MOLECULAR PATHWAYS INVOLVED 
IN PTRIC
We speculate that PTRIC is mediated by 
treatment-associated, hypoxia-regulated stimulation of 
glioma or peritumoral endothelial cells with subsequent 
attraction and migration of bone marrow-derived 
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cells (BMDCs), neural stem cells (NSCs), or even possibly 
glioma stem cells (GSCs). This is based on prior studies 
that have demonstrated that BMDCs and glioma tumor 
stem-like cell recruitment and vasculogenesis is mediated 
by hypoxia-regulated proteins including HIF-1 and 
SDF-1/CXC-12.[1,3,8,13,15,16,27,34,40] In a similar manner, human 
umbilical cord blood stem cells show platelet-derived 
growth factor-D-dependent glioma cell tropism in vitro and 
in vivo.[17] To test these ideas, we hope to further develop our 
rodent model of PTRIC and apply novel imaging modalities 
to distinguish PTRIC from true tumor progression.
CONCLUSIONS
Response to treatment of patients with GBM is usually 
measured by gadolinium-enhanced MRI; however, up to 
one-third of patients will develop posttreatment radiographic 
changes that can mimic tumor progression. These changes 
can influence clinicians to make treatment decisions 
that are inappropriate for the patient’s actual clinical 
condition. Not much is known about the tumor biology of 
pseudoprogression, with only a limited number of predictive 
biomarkers available. Several imaging modalities have been 
used to try to distinguish PTRIC and true progression, 
Figure 2: Tumor progression. (a) Correlation of bioluminescence imaging (top row) and T1-weighted gadolinium-enhanced MRI (coronal 
views, 2nd row and axial views, 3rd row) and T2-weighted MRI (coronal views, 4th row) over time. Time labels at time represent time of tumor 
implantation and establishment (Day-7 and -3), start of radiation (2 Gy, three treatments given over 5 days) with no chemotherapy (Start 
Tx), and days after treatment started. (b) Graphic representation of luciferase activity and gadolinium-enhanced MRI tumor volume over 
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including conventional MRI, perfusion MRI, MR 
spectroscopy, and PET; however, none of these modalities has 
consistently and reliably distinguished PTRIC from tumor 
growth. We describe preliminary work on an animal model 
using glioma cells transfected with a luciferase reporter. 
After conventional GBM therapy, this animal model can 
be evaluated with posttreatment bioluminescence imaging 
and various MR tumor imaging modalities. We hope to use 
this model for mechanistic studies to determine causes and 
potential treatments for PTRI C.
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